Moffitt Cancer Center focuses on these risks in its new international compliance program (see story, p. 1)[1] and has mitigation strategies for all of them, said Chief Compliance Officer Donnetta Horseman. For example, with respect to biologicals, “International Compliance should review all new biosafety protocols as they are presented to the biosafety review board. A team member from international compliance should also attend biosafety committee meetings as needed to hear more about certain biologicals and their use within the protocol.” Contact her at donnetta.horseman@moffitt.org.